Physician

Ravin Jain Garg, M.D.

According to 2025 Medicare claims, Ravin Garg, M.D. (NPI: 1043385180) practices medical oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Anne Arundel, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21401-9998. Garg is affiliated with the Aledade 61 WA CCCN CHC MSSP Enhanced (ACO ID: A4777), participating under the MSSP model.

Garg's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 807 traditional Medicare patients, billed 269,281 HCPCS/CPT codes, and received $5,785,273 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,332 prescription claims across 215 beneficiaries totaling $3,586,309 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 30 claims. Open Payments data shows 7 records totaling $190. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $102,306 to $5,785,273. Similarly, Part D prescription costs have risen steadily, from $944,444 to $3,586,309. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,170 to $536.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	547	1,442	$102,306
2016	580	1,561	$100,802
2017	606	1,557	$109,227
2018	712	4,775	$217,546
2019	711	7,467	$336,764
2020	669	35,034	$869,000
2021	557	189,008	$3,373,391
2022	609	274,490	$4,912,047
2023	642	280,533	$5,973,015
2024	807	269,281	$5,785,273

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	131	682	$944,444
2016	149	866	$1,487,148
2017	164	989	$2,084,621
2018	223	1,165	$2,199,776
2019	222	1,334	$2,578,759
2020	195	1,029	$1,908,388
2021	182	947	$1,651,810
2022	188	1,286	$2,191,177
2023	192	1,168	$2,229,437
2024	215	1,332	$3,586,309

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	97	$9,043
2016	N/R	73	$8,888
2017	51	124	$21,034
2018	83	249	$26,764
2019	N/R	65	$6,526
2020	N/R	23	$2,342
2021	N/R	34	$2,582
2022	N/R	95	$2,712
2023	N/R	49	$6,727
2024	N/R	30	$868

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	139	565	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	345	961	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	314	403	$68
96375	Injection of additional new drug or substance into vein	97	552	$12
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	460	1,734	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	39	1,092	$622,677
Venclexta	Venetoclax	25	761	$399,616
Revlimid	Lenalidomide	17	476	$361,371
Pomalyst	Pomalidomide	14	392	$341,622
Ojjaara	Momelotinib Dihydrochloride	12	360	$332,019

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$567
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$190	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ravin Jain Garg, M.D.?

Tedicare shows public-source Medicare data for Ravin Jain Garg, M.D. (NPI 1043385180), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ravin Jain Garg, M.D. have ACO affiliation data?

Ravin Jain Garg, M.D. is shown with ACO affiliation data for Aledade 61 WA CCCN CHC MSSP Enhanced (MSSP, ACO ID A4777).

What billing organization is linked to Ravin Jain Garg, M.D.?

Ravin Jain Garg, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Ravin Jain Garg, M.D. have Open Payments data?

Ravin Jain Garg, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.